SCHEMBL5758752

SCHEMBL5758752

COCCn1cc(C(=O)NCc2ccc3c(c2)OCO3)c(=O)n(-c2cccc(Cl)c2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.55
TSHR P16473 4/20 0.55
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
ALDH1A1 P00352 4/20 0.52
LMNA P02545 2/20 0.52
PKM P14618 2/20 0.52
POLB P06746 2/20 0.52
MCL1 Q07820 1/20 0.52
HKDC1 Q2TB90 1/20 0.52
USP2 O75604 1/20 0.51
MAPK1 P28482 3/20 0.48
ALOX15 P16050 2/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH2 P05091 1/20 0.48
APOBEC3A P31941 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756706 0.90 KMT2A (0.53) HPGDTSHRGAAKMT2AMEN1
SCHEMBL5756748 0.90 HPGD (0.53) HPGDTSHRGAASMN1; SMN2KMT2A
SCHEMBL5756461 0.87 PDE10A (0.48) KMT2ALMNAMAPT
SCHEMBL5759410 0.86 PDE10A (0.48) HPGDTSHRKMT2ALMNA
SCHEMBL5758891 0.85 PDE10A (0.50) KMT2A
SCHEMBL5759073 0.85 TP53 (0.49) HPGDKMT2AMEN1LMNAPOLB
SCHEMBL5759479 0.85 PDE10A (0.48)
SCHEMBL5759317 0.85 TP53 (0.52) KMT2ALMNAMAPT
SCHEMBL5760095 0.84 ALDH1A1 (0.55) HPGDTSHRGAASMN1; SMN2KMT2A
SCHEMBL5758809 0.84 PDE10A (0.45) KMT2ALMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
CN-1711243-A 2-pyridone derivatives as inhibitors of neutrophil elastase ASTRAZENECA AB (SE) 2005-12-21 CN disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 HPGD 170/4885TSHR 3004/4885GAA 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.